Pembrolizumab plus Chemotherapie als Erstlinientherapie beim fortgeschrittenen Ösophaguskarzinom (KEYNOTE-590)Pembrolizumab plus chemotherapy as first-line treatment in advanced oesophageal cancer (KEYNOTE-590)

被引：0
|
作者：
Milan Hartmann
Thomas Zander
Hakan Alakus
机构：
[1] Universitätsklinikum Köln (AöR),Klinik und Poliklinik für Allgemein‑, Viszeral‑, Tumor
[2] Universitätsklinikum Köln, und Transplantationschirurgie
来源：
Der Onkologe | 2022年 / 28卷 / 5期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：436 / 437
页数：1
相关论文
共 50 条
  • [31] KEYNOTE-426 Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
    Bedke, J.
    Stuehler, V.
    UROLOGE, 2020, 59 (07): : 841 - 842
  • [32] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
  • [33] First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
    Robinson, A. G.
    Vicente, D.
    Tafreshi, A.
    Parra, H. Soto
    Mazieres, J.
    Cicin, I.
    Medgyasszay, B.
    Rodriguez-Cid, J.
    Okamoto, I.
    Lee, S.
    Ramlau, R.
    Vladimirov, V.
    Cheng, Y.
    Halmos, B.
    Liu, C-C.
    Schwarzenberger, P.
    Piperdi, B.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S748 - S749
  • [34] A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress
    Kato, K.
    Shah, M.
    Enzinger, P.
    Bennouna, J.
    Shen, L.
    Adenis, A.
    Sun, J.
    Cho, B.
    Ozguroglu, M.
    Kojima, K.
    Kostorov, V.
    Hierro, C.
    Zhu, Y.
    Shah, S.
    Bhagia, P.
    Doi, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [36] Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
    Lee, Keun-Wook
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Lee, Jeeyun
    Castro, Hugo R.
    Chao, Joseph
    Wainberg, Zev A.
    Cao, Z. Alexander
    Aurora-Garg, Deepti
    Kobie, Julie
    Cristescu, Razvan
    Bhagia, Pooja
    Shah, Sukrut
    Tabernero, Josep
    Shitara, Kohei
    Wyrwicz, Lucjan
    CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3489 - 3498
  • [37] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [38] Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update
    Borghaei, H.
    Langer, C.
    Gadgeel, S.
    Papadimitrakopoulou, V.
    Patnaik, A.
    Powell, S.
    Gentzler, R.
    Martins, R.
    Stevenson, J.
    Jalal, S.
    Panwalkar, A.
    Yang, J. C.
    Gubens, M.
    Sequist, L.
    Awad, M.
    Fiore, J.
    Saraf, S.
    Raftopoulos, H.
    Gandhi, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1791 - S1791
  • [39] Phase 3 study of epacadostat plus pembrolizumab with or without platinumbased chemotherapy vs pembrolizumab plus chemotherapy for first-line metastatic non-small cell lung cancer (mNSCLC): ECHO-306/KEYNOTE-715
    Garassino, M.
    Rubin, S.
    Zhao, Y.
    Luo, Y.
    Samkari, A.
    Hui, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S115 - S115
  • [40] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345